Rational Control of Antibody Orientation for Enhancing Sensitivity and Specificity in Lateral Flow Immunoassays With Clinical Validation
Advanced Healthcare Materials · 2026-11 · 15 (41)
DOI: 10.1002/adhm.71815 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Healthcare Materials, online erschienen am 09.10.2026. Verfasst von Pin-Hao Wang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Applied Chemistry, National Yang Ming Chiao Tung University, Hsinchu, Taiwan. Hauptthemen laut MEDLINE: Antibodies. Die Arbeit nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Science and Technology Council.
Abstract (Originalsprache)
Lateral flow assays (LFAs) are widely used for point‐of‐care diagnostics, but their sensitivity is often limited by inefficient antibody orientation and poor signal transduction. Herein, we report a universal strategy integrating orientation‐controlled antibody conjugation at the immunoprobe with a biotin‐streptavidin‐modified test line to enhance LFA sensitivity, specificity, and analytical reliability. Using an orientation‐controlled conjugation approach (P‐6, Scheme 1), antigen accessibility was maximized while nonspecific adsorption and false‐positive signals were suppressed. Compared with conventional randomly conjugated probes (P‐3, Scheme 1) on unmodified test lines, the combined P‐6/biotin‐streptavidin configuration achieved limits of detection of 0.0352 ng/mL for cytokeratin 19 fragment (CYFRA21‐1) and 0.0808 ng/mL for carcinoembryonic antigen (CEA), corresponding to sensitivity enhancements of approximately 14–19 fold. However, probe rankings get inverted across capture chemistries, indicating the importance of dual‐site orientation. The universality of this strategy was further validated using alpha‐fetoprotein (AFP), carbohydrate antigen 125 (CA125), carbohydrate antigen 15‐3 (CA15‐3), and prostate‐specific antigen (PSA). Furthermore, multiplexed LFAs using fluorescent polymer dots enabled simultaneous detection of CYFRA21‐1 and CEA with minimal cross‐reactivity and were validated in 28 clinical serum samples against the hospital reference method.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Applied Chemistry, National Yang Ming Chiao Tung University, Hsinchu, Taiwan.
- Department of Materials Science and Engineering, National Yang Ming Chiao Tung University, Hsinchu, Taiwan.
- Department of Surgery, National Taiwan University Hospital, Hsinchu, Taiwan.
- Center For Emergent Functional Matter Science, National Yang Ming Chiao Tung University, Hsinchu, Taiwan.
- Department of Medicinal and Applied Chemistry, Kaohsiung Medical University, Kaohsiung, Taiwan.
ORCID-Profile: Pin-Hao Wang, Shunmuga Nathan Shunmuga Nainar, Yang-Hsiang Chan
Förderung
- National Science and Technology Council
Zitieren
APA
Wang, P. H., Shunmuga Nainar, S. N., Zhuang, B. H., Yang, S. M., Lin, H. C., & Chan, Y. H. (2026). Rational Control of Antibody Orientation for Enhancing Sensitivity and Specificity in Lateral Flow Immunoassays With Clinical Validation. Advanced Healthcare Materials, 15(41). https://doi.org/10.1002/adhm.71815
Vancouver
Wang PH, Shunmuga Nainar SN, Zhuang BH, Yang SM, Lin HC, Chan YH. Rational Control of Antibody Orientation for Enhancing Sensitivity and Specificity in Lateral Flow Immunoassays With Clinical Validation. Advanced Healthcare Materials. 2026;15(41). doi:10.1002/adhm.71815
BibTeX
@article{Wang2026,
author = {Wang, Pin-Hao and Shunmuga Nainar, Shunmuga Nathan and Zhuang, Bing-Han and Yang, Shun-Mao and Lin, Hong-Cheu and Chan, Yang-Hsiang},
title = {Rational Control of Antibody Orientation for Enhancing Sensitivity and Specificity in Lateral Flow Immunoassays With Clinical Validation},
journal = {Advanced Healthcare Materials},
year = {2026},
volume = {15},
number = {41},
doi = {10.1002/adhm.71815}
}
EUVIMED